Andreas Merkenschlager

Leipzig University
Country flagGermany

Research Interests

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Explore related searches

Articles (7)

Year:

2026

Year:

2026

Background: Risdiplam is approved for the treatment of 5q-SMA from birth for all types and stages. However, broader data for adults are scarce. We aimed to assess safety and efficacy of risdiplam in adults with SMA. Methods: This is an observational cohort study at 38 academic clinical sites in German-speaking countries. Patients with genetically confirmed 5q-SMA (age 16–69 years) were included and received risdiplam treatment for a minimum treatment time of 6 months to a follow-up of up to 30 months. Primary outcome was the change in the total Revised Upper Limb Module (RULM) score, assessed at baseline to months 4-6, 12-14 and 28-30, and based on pre–post comparisons. This study is registered with the German Clinical Trials Register (DRKS00012699). Findings: Risdiplam showed significant motor improvement across a wide phenotypic spectrum of adult SMA patients regardless of age, SMN2 copy number, and functional status. 74% of patients improved or stabilized at 30 months in RULM; patients do not only deteriorate less rapidly but continue to stabilize or even improve at later time points. Maximum RULM improvement was 1.37 points in SMA3 patients at month 12/14, while at all other timepoints, both in SMA1 and SMA2 patients, mean RULM improvement was below 1 and at all time points below the CMC of 2. We did not detect a correlation between RULM improvement and age, sex or body weight, nor significant changes in HFMSE and 6MWT. No new safety findings were detected. Interpretation: Our study provides real-world data from the multinational SMArtCARE registry on efficacy and safety of risdiplam in 194 adult ambulatory and non-ambulatory SMA patients over 4-30 months of treatment. Funding: Financial support for the SMArtCARE registry is provided by Biogen, Novartis and Roche. Declaration of Interest: BS, BK, CB, CS, CR, EH, GSa, GS, MS, OS and VP declare no conflicts of interest. AB received honoraria for advisory board attendance, speaker’s fees from Biogen, Novartis, Roche, Italpharmaco, SantheraMT received honoraria for advisory board attendance, speaker’s fees and research funding from Alexion, Amicus, AstraZeneca, Sanofi Genzyme, Takeda, outside of the present work. AE received speakers´ fees and honoraria for advisory board attendance from Novartis, Biogen, Roche AH received funding for Travel and/or Speaker Honoraria from Roche, Biogen, Novartis, PTC Therapeutics, Santhera, Biomarin, and Takeda. He received research support from Roche, Sanofi, Takeda, Biomarin. AR received speaker fees from Amylyx Pharmaceuticals, ROCHE, Argenx, UCB Pharma, Alexion Pharma, Zambon and ITF Pharma, travel support for congress from Zambon and Johnson&Johnson and served on advisory boards for Biogen and Argenx, outside of the submitted work. ASN reports Adborad Meetings with Roche, Biogen, Novartis and Santhera Pharmaceuticals. CN received honoraria for advisory board attendance, speaker’s fees and travel grants from Biogen USA, Biogen Switzerland, Roche, Sanofi Genezyme, Mitsubishi Tanabe, Alexion, Argenx, Amicus, Johnson & Johnson, Amgen, Jannsen DH received honoraria for advisory board attendance from Novartis. DZ received honoraria for advisory board attendance from Biogen and Amicus, for consultancy from Novartis, and travel support for conference attendance from Zambon, outside of the present work. FK received speaker honoraria from Roche, Amicus, Alexion, Sanofi; travel support for conference attendance from Roche, ITF Pharma and Amicus, and served on advisory boards for Amicus, Roche, and Abcuro. GMzH received compensation for serving on scientific advisory boards (JnJ, Immunovant), speaker honoraria (Amgen, Argenx) and scientific project funding (Biogen). GW has received honoraria for advisory board attendance, speaker’s fees from Roche, Novartis, Alnylam and AstraZeneca outside of the present work. HC received honoraria for advisory board attendance, speaker’s f

Year:

2026

Background: PTEN hamartoma tumor syndrome (PHTS) has evolved into an umbrella term for a range of syndromes, characterized by loss-of-function variants in the phosphatase and tensin homolog (PTEN) tumor suppressor gene on chromosome 10q23.31. This can result in a lifelong tumor predisposition in patients. Often, the syndrome is diagnosed in early childhood because of macrocephaly, dermatological findings, or development delay. Since the correlation between phenotype and genotype is weak, and the penetrance is age-dependent, this poses the question of the appropriate timing of potentially invasive and burdensome examinations for early cancer detection. Case: The present report describes an infant with cleft palate associated with PHTS, a rare occurrence, though the initial report of Cowden syndrome already pointed to oromaxillofacial abnormalities. The recent pediatric literature is reviewed to assess which clinical symptoms should raise suspicion of PHTS and may then lead to early genetic counseling. Conclusion: Since the amount of prospective data remains limited, and the estimation of tumor risk during infancy and adulthood is very difficult, we advocate for early and broad genetic testing in suspected cases, to gain more insights into this rare disease and allow for better counseling for patients and their families.

Year:

2025

Fatal and nonfatal drowning are among the leading causes of death and lifelong severe neurological impairment among children and adolescents. This study aimed to complement research from Leipzig 1994–2008 to seek trends within risk factors, treatments, and outcomes throughout the last decade. We retrospectively investigated data of 47 inpatients aged 0–18 admitted to Leipzig University Department of Pediatrics who matched ICD-10 code T75.1 from 2008 to 2020 and compared them to a preceding study at the same institution. We also examined the prognostic value of parameters regarding the patients’ outcomes. There were three median incidents per annum. The median age was 2.75 years; 76% of incidents happened in males. An accumulation was seen during the summer months and weekends. Most drowning incidents occurred in private ponds or pools (48.9%). Thirty-nine children were discharged without resulting morbidity, four showed neurological impairment, and three died. Risk factors concerning age, sex, and incident characteristics were confirmed. Special supervision needs still apply to 1–3-year-old male children or children with pre-existing health conditions around private pools and ponds. Hospitalization duration shortened, and morbidity and lethality decreased since the previous study. There was structural improvement in primary care and medical documentation. Parameters suggesting good outcomes include a submersion time < 5 min, GCS > 3 points, spontaneous movement upon admission, remaining pupillary light response, the absence of cardiovascular arrest, body temperature ≥ 32 °C, pH > 7, blood glucose < 15 mmol/L, lactate < 14 mmol/L, base excess ≥ −15 mmol/L, and the absence of ARDS. Clear legislation can contribute to improved private home water safety. Further studies should include a broad in- and outpatient spectrum and standardized incident documentation presupposing Utstein-style reporting. Regular reinvestigation of consistent geographical regions facilitates process evaluations of drowning epidemiology and therapy evolution.

Year:

2024

Background ADCY5-related dyskinesia is a rare disorder caused by mutations in the ADCY5 gene resulting in abnormal involuntary movements. Currently, there are no standardized guidelines to treat this condition. Objectives The aim of this study is to evaluate the efficacy of theophylline administration in improving symptoms and quality of life in patients with ADCY5-related dyskinesia. Methods A retrospective study was conducted involving 12 patients (aged 2-34 years) with ADCY5-related dyskinesia. Participants completed a questionnaire about theophylline administration, including dosage, improvement of symptoms, adverse effects, and changes in quality of life. Data were analyzed for reported efficacy and side effects. Results Theophylline administration demonstrated substantial efficacy, with 92% (11 out of 12) of patients reporting significant improvements in their movement disorders. The average improvement score was 7.0 (± 1.9) on a 10-point scale. Notable improvements included reductions in severity and frequency of episodes, improved gait, more independent mobility, psycho-social well-being, and quality of sleep. Adverse effects were reported by 6 patients, including dystonia, speech worsening, headaches, nausea, impaired sleep, and agitation. Conclusions Theophylline shows substantial promise as a treatment option for ADCY5-related dyskinesia, improving various aspects of patients’ quality of life and movement disorder symptoms. Further research is needed to optimize dosing, to understand long-term effects, and to explore combinational drug therapies. Despite the small cohort size and the retrospective nature of this study, the results support theophylline administration to decrease dyskinetic movements and enhance overall quality of life in patients.

Year:

2024

Purpose: The aim of this study was to collect further data to estimate the risk of relevant intracranial pathology and thereby better assess the need for cranial imaging in children with acute acquired comitant esotropia (AACE). To date, there is still not enough literature on this topic to enable a consensus on the diagnostic algorithm. Methods: We analyzed data from patients with convergent strabismus who received cranial imaging via magnetic resonance imaging (MRI). Twenty-one patients received a cranial MRI for the diagnostic evaluation of AACE. The age range was from 2 to 12 years, and the mean age at the time of diagnosis was 5.5 years. Of these patients, only one exhibited insignificant MRI findings, with no therapeutic consequences. Conclusions: Our data add further evidence that AACE without neurological findings or other ophthalmologic anomalies might not be an indication for cranial MRI as a diagnostic screening tool.

Year:

2024

Collaborators (20)

Christoph Neuwirth

Deputy Head

Kantonsspital St. Gallen

SWITZERLAND
View details

Wolfgang Löscher

Medical University of Innsbruck

AUSTRIA
View details

Markus Weiler

Prof. Dr

University Hospital Heidelberg

GERMANY
View details

Janina Gburek-Augustat

University Hospital Leipzig

GERMANY
View details

Christoph Kleinschnitz

Head of Department

University Hospital Essen

GERMANY
View details

Omar Keritam

Medical University of Vienna

AUSTRIA
View details

Susanne Petri

Associate Professor

Hannover Medical School

GERMANY
View details

Daniel Zeller

University Hospital Würzburg

GERMANY
View details

Gerd Meyer zu Horste

Heisenberg-Professor and Attending Neurologist

-

GERMANY
View details

Marcus Deschauer

-

GERMANY
View details

Andrea Sinz

-

GERMANY
View details

Ralf A. Husain

Consultant neuropediatrician/ head of Centre of Inborn Errors of Metabolism

University Children's Hospital

GERMANY
View details

Maggie C. Walter

Associate Professor of Neurology

Friedrich-Loeffler-Institut

GERMANY
View details

Matthias Baumann

Medical University of Innsbruck

AUSTRIA
View details

Georges Sam

University Hospital Heidelberg

GERMANY
View details

Robin-Tobias Jauss

Staff Scientist

University Hospital Leipzig

GERMANY
View details

Hakan Cetin

-

AUSTRIA
View details

Hanns Lochmüller

Senior Scientist

-

CANADA
View details

Vincent Strehlow

-

GERMANY
View details

Regina Trollmann

Head of Pediatric Neurology/Prof. Dr. med

Friedrich-Alexander Universität Erlangen-Nürnberg

GERMANY
View details